With $50 million in hand from Flagship Pioneering, Abiologics Inc. is pairing generative artificial intelligence with high-throughput chemical protein synthesis to attack oncology and immunology indications with Synteins, synthetic proteins that represent a new class of programmable medicines. Avak Kahvejian, co-founder and CEO of Abiologics and general partner at Flagship, told BioWorld that Abiologics stands “at the precipice of a completely new modality.” Read More
Long-acting glucagon-like peptide-1 receptor (GLP-1R) agonists have shown efficacy in obesity treatment but, after discontinuation, a rapid recovery of weight is usually seen, likely due to orexigenic mechanisms involved in weight regain. Read More
Integrase strand transfer inhibitors (INSTI) under a once-daily oral schedule are the standard-of-care treatment for HIV. Longer-acting oral and injectable formulations to facilitate adherence to treatment regimens are needed. Read More
Arrhythmogenic cardiomyopathy (ACM) is a severe genetic cardiac disorder caused by mutations in some desmosomal genes. The most frequently affected gene in patients with ACM is PKP2, the loss of which provokes desmosomal instability that leads to activation of downstream disease processes ultimately resulting in life-threatening ventricular arrhythmia and heart failure. Read More
Shanghai Wennai Pharmaceutical Technology Co. Ltd. has described new cholesterol side-chain cleavage enzyme, mitochondrial (CYP11A1) inhibitors reported to be useful for the treatment of breast and prostate cancer. Read More
Zyversa Therapeutics Inc. has selected obesity and its related metabolic complications as the lead indication for its inflammasome ASC inhibitor IC-100. Read More
From no hope to viable treatments, BioWorld is there to cover the breakthroughs in medicine. Listen to Randy Osborne explain why the BioWorld team is ‘always on the lookout for what's next.’ Read More
Iaso Biotechnology Co. Ltd. has announced that China’s National Medical Products Administration (NMPA) has approved the IND application for IASO-782 injection for a new indication – systemic lupus erythematosus. Read More
Medipol Ueniversitesi Zonguldak Buelent Ecevit University has patented new specific arylidene barbiturate derivatives reported to be useful for the treatment of cancer. Read More
Genechem Inc. has created conjugates comprising gemcitabine covalently linked to sialyllactose through a linker and reported to be useful for the treatment of cancer. Read More
Dren Bio Inc. has entered into a strategic collaboration with Novartis Pharma AG which will focus on the discovery and development of therapeutic bispecific antibodies for cancer leveraging Dren Bio’s proprietary Targeted Myeloid Engager and Phagocytosis Platform. Read More
Vidac Pharma Holdings plc has released the results of preclinical studies with VDA-1275 in multiple mouse cancer and human cellular organoid models of solid tumors. Read More
